Browse grants

National Institutes of Health · Up to $250K

This NIH/National Library of Medicine R01 funds development of informatics and data science approaches that give individuals actionable insights into their own health; a clinical trial is optional. Eligible applicants include universities, research institutions, and tribal and community organizations, and foreign organizations are listed among eligible applicants. The maximum award is about $250,000. It requires informatics research capacity.

National Institutes of Health · Amount varies

This NIH/National Cancer Institute R01 supports investigator-initiated clinical trials in cancer prevention and control, such as early detection, screening, and survivorship research. Typical applicants are universities, research institutions, hospitals, tribal organizations, and government and community organizations; foreign organizations are listed among eligible applicants here. A qualifying clinical trial is required, so it is geared toward established research teams. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIH/National Cancer Institute R01 funds investigator-initiated early-phase (Phase 0, I, II) clinical trials for cancer diagnosis and treatment; a clinical trial is required. Eligible applicants include universities, research institutions, hospitals, tribal and community organizations, and foreign organizations. The maximum award is just under $500,000. It is geared toward established clinical research teams.

National Institutes of Health · Amount varies

This NIH R01 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations; a clinical trial is optional. It requires established research capacity in this area. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH R21 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk; no clinical trial is allowed. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations. It requires research capacity in this area. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIH/National Cancer Institute R01 funds academic-industrial partnerships to translate and validate in vivo imaging, data science, or spectroscopic technologies into tools for cancer and other diseases; a clinical trial is optional. Eligible applicants include universities, research institutions, and tribal and community organizations, and foreign organizations are listed among eligible applicants. The award maximum is about $500,000, and the model assumes an academic-industry collaboration. It is aimed at research teams.

National Institutes of Health · Up to $350K

This NIH HEAL Initiative R61/R33 funds early translational drug-discovery research toward non-addictive pain therapeutics, including assay development, screening, and initial characterization of candidate agents; no clinical trial is allowed. Eligible applicants include universities, research institutions, and tribal and community organizations, but foreign organizations are not eligible to apply. The maximum award is about $350,000. It requires drug-discovery research capacity.

National Institutes of Health · Amount varies

This NIH (R61/R33) phased opportunity funds mechanistic research to advance precision probiotic therapies, beginning with an exploratory phase to identify person-specific factors and a second phase to test them in animal models or human subjects, over a combined period of up to five years. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Transition between phases depends on meeting milestones. It is intended for established research teams, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (R33) opportunity funds mechanistic research to advance precision probiotic therapies by characterizing person-specific factors that affect probiotic responses, using animal models or human subjects. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. It expects supportive preliminary data and is intended for established research teams, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific types of NIH grants and need to transfer an existing award to a new recipient institution (a change of recipient organization). It is an administrative prior-approval request, not a new funding opportunity, and there is no guarantee a transfer will be approved. Only current NIH grantee organizations should apply; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific NIH grants and need to transfer an award due to a change in organizational status (successor-in-interest). It is an administrative prior-approval request, not a new funding opportunity, and approval of the transfer is not guaranteed. Only current NIH grantee organizations should use it; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

This NIH program supports preclinical discovery and development of biologic-based therapies for nervous system disorders, from lead optimization through Phase I clinical testing. Eligible applicants are research organizations such as universities, colleges, government and tribal agencies, faith- or community-based organizations, and (for this announcement) foreign organizations; it is geared toward established research teams, not individuals or general nonprofits. Award amounts are not specified. Applicants should be prepared for a complex, multi-phase research undertaking with NIH-funded consultants and contract research organizations.

National Institutes of Health · Amount varies

This NIH (R21) opportunity supports exploratory research in computational genomics, data science, statistics, and bioinformatics relevant to basic or clinical genomic science and human health. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it is intended for established research teams rather than individuals or general nonprofits. Award amounts are not specified. Methods should be generalizable and scalable to large datasets.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds research in computational genomics, data science, statistics, and bioinformatics relevant to basic or clinical genomic science and broadly applicable to human health. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it targets established research teams rather than individuals or general nonprofits. Award amounts are not specified. Methods are expected to be generalizable and scalable to large datasets.

National Institutes of Health · Amount varies

This NIH (U01) program funds academic-industry research partnerships that develop and advance bioengineering tools and technologies to address biomedical problems, aiming for solutions deployable within roughly 5-10 years. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it is geared toward multidisciplinary research teams partnered with industry, not individuals or general nonprofits. Award amounts are not specified. Applicants should expect a collaborative, milestone-driven structure.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds non-pharmacological interventions to promote sleep health and reduce sleep-related health disparities among populations that experience health disparities. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply. It is intended for established research teams, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (R13) program supports conferences and scientific meetings relevant to public health and the missions of participating NIH institutes. Eligible applicants are U.S. research and education organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Note that R13 conference support typically requires advance permission from the funding institute before applying. It is aimed at organizations hosting scientific conferences, not individuals. Award amounts are not specified.

National Institutes of Health · Up to $100K

This NIH (NIDA, R03) award helps investigators enter addiction-related data science, supporting small-scale projects that apply emerging data science methods or generate preliminary data for larger studies, with a budget cap around $100,000. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it is intended for investigators at research institutions, not individuals or general nonprofits. It encourages use of existing datasets and FAIR principles. Confirm program-specific eligibility in the full announcement.

National Institutes of Health · Amount varies

This NIH (NCI, U01) program funds research on how preanalytical variability in handling tumor tissue, blood, and other biospecimens affects clinically relevant biomarkers, to support standardization of biopsy handling and clinical assay development. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it targets established research teams, not individuals or general nonprofits. Award amounts are not specified. Confirm program-specific eligibility in the full announcement.

National Institutes of Health · Amount varies

This NIH/NCI U01 funds cancer etiology and early-detection biomarker research that must use the NCI-sponsored PLCO Screening Trial biospecimen resource. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations, not individuals. No award amount is specified. Projects that do not use PLCO biospecimens will not be funded, which narrows eligibility significantly.